Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
Mathilde Bureau, Thierry Chatellier, Tanguy Perennec, Thomas Goronflot, Charlotte Greilsamer, Anne‐Laure Chené, Raafet Affi, Éric Frampas, Jaafar Bennouna, Elvire Pons‐Tostivint
Topics & Concepts
PembrolizumabMedicineInternal medicineLung cancerUnivariate analysisChemotherapyClinical endpointGastroenterologyRetrospective cohort studyCancerOncologySurgeryMultivariate analysisImmunotherapyClinical trialCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging